0 results available. Select is focused ,type to refine list, press Down to open the menu,
Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The compan...
The following section summarizes insights on Inozyme Pharma Inc's Shareholder Yield:
We've identified the following companies as similar to Inozyme Pharma Inc because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.
To view the full list of supported financial metrics please see Complete Metrics Listing.
Metrics similar to Shareholder Yield in the valuation category include:
A ratio that measures the total amount of money the company is returning back to shareholders in the form of cash dividends, net stock repurchases, an...
Shareholder Yield is defined as:
Net Payout Yield
(+) Debt Paydown Yield
(=) Shareholder Yield
Shareholder yield measures the return shareholders receive from a company in the form of cash dividends, stock buybacks, and debt reduction.
Net Payout Yield measures the cash dividend plus net stock repurchases over the trailing twelve months divided by the company’s market capitalization
Debt Paydown Yield is the amount debt paid down minus the amount of debt issued over the trailing twelve months divided by the company’s market capitalization
Applying this formula, Inozyme Pharma’s Shareholder Yield is calculated below:
Net Payout Yield [ −17.7% ]
(+) Debt Paydown Yield [ −0.4% ]
(=) Shareholder Yield [ −18.2% ]
The tables below summarizes the trend in Inozyme Pharma’s shareholder yield over the last five years:
| Date | Net Payout Yield | Debt Paydown Yield | Shareholder Yield |
|---|---|---|---|
| 2020-12-31 | −24.1% | 0.0% | −24.1% |
| 2021-12-31 | −0.4% | −2.2% | −2.6% |
| 2022-12-31 | −162.1% | −7.9% | −170.0% |
| 2023-12-31 | −32.7% | −10.3% | −43.0% |
| 2024-12-31 | −17.7% | −0.4% | −18.2% |
Read more about buyback yield, net payout yield, and debt paydown yield
The chart above depicts the distribution of shareholder yield for companies operating in the Healthcare sector in the Developed economic region. Over 2,450 companies were considered in this analysis, and 2,363 had meaningful values. The average shareholder yield of companies in the sector is -28.2% with a standard deviation of 82.5%.
Inozyme Pharma Inc's Shareholder Yield of -18.2% ranks in the 30.0% percentile for the sector. The following table provides additional summary stats:
| Economic Risk Region | Developed |
| Total Constituents | 2,459 |
| Included Constituents | 2,363 |
| Min | -716.2% |
| Max | 82.9% |
| Median | -3.1% |
| Mean | -28.2% |
| Standard Deviation | 82.5% |
You can find companies with similar shareholder yield using this stock screener.